 |
 |
Mar 26, 2009 10:12 ET Change in US Stem Cell Policy Could Create Half Billion Dollar Market Stem Cell Therapeutics NEW YORK, NY--(Marketwire - March 26, 2009) - The stem cell industry is expected to thrive in the United States now that President Barack Obama has lifted the federal funding restrictions on stem cell research, reversing the limits imposed by President Bush on the use of embryonic stem cells more than seven years ago. According to Kalorama Information's analysts, there could be a $500 million dollar world market for these types of therapies by 2013; now that the world's largest healthcare economy can participate in development. Leading life science market research publisher Kalorama Information notes in its new report "Stem Cell Therapeutics Markets" that under a best case scenario where therapies are successful, regulatory acceptance is expedient and insurers cover new therapies, the market could grow over thirty times its estimated size of $16.4 million in 2008. "Since there are just a few products in this area now, our analysts have used a bottom-up model to make forecasts, based on disease incidence and a gradual replacement of current therapies," said Bruce Carlson, publisher for Kalorama information. "In the past, analysts have utilized models like this to predict monoclonal antibody and cancer vaccine markets, before viable products appeared." Kalorama estimates that half of stem cell therapeutics revenue will be in cardiovascular disease, with lung disease, cancer and diabetes treatments making up the lion's share of the rest. The previous lack of funding for basic research, compared with the technological challenges that must be overcome, has resulted in very limited approvals of new drug therapies that involve stem cells, despite strong potential. As of the end of 2007, there were no approved treatments or human trials using embryonic stem cells in the U.S. Any existing therapies were typically in the form of stem cell transplants using either bone marrow or blood stem cells for oncological conditions. "This situation has allowed other countries to take the lead," noted Carlson. "The UK is responsible for many of the advances in stem cell technology, and both China and Singapore, with some of the most unrestrictive embryonic stem cell research policies in the world, have emerged in this area." But things should change with the new federal policies and America's gain may be Europe and Asia's loss, since money from American companies has been funding many projects abroad, some of which will likely relocate. Still, despite a short drop in European and Asian projects, the U.S. is the world's largest healthcare market which should alleviate any loss in global revenues. Kalorama Information's new report, "Stem Cell Therapeutics Markets," breaks down forecasted revenues and procedure volumes for stem cell therapeutics in a variety of disease areas, discusses issues and trends, and reviews current and developing therapies. For further information visit: http://www.kaloramainformation.com/redirect.asp?progid=68002&productid=2021959 Rayilyn Brown Director AZNPF Arizona Chapter National Parkinson Foundation [log in to unmask] ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn